Guardant Health: Four reasons for a successful Breakout
The oncology testing volume increased by 40% in Q3
Starting from Q1 2026, a partnership with Quest Diagnostics will expand distribution
Reading Time: 1 minute
In the current market environment, I am increasingly focusing on growth stocks that demonstrate relative strength. The diagnostics company Guardant Health (GH) is one of my favorites for a breakout trade for the following reasons: Guardant Health covers the entire spectrum of cancer detection with minimally invasive blood tests. Growth in Guardant360 Liquid, Guardant360 Tissue, and Reveal is accelerating in Q3, leading to an annualized revenue of over $1 billion for the first time. Extensions of Guardant360 CDx for tumor profiling and Reveal...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
